- Oops!Something went wrong.Please try again later.
Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO.
How Does Vinnie, Vin Milano's Compensation Compare With Similar Sized Companies?
According to our data, Idera Pharmaceuticals, Inc. has a market capitalization of US$55m, and paid its CEO total annual compensation worth US$1.8m over the year to December 2018. While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$600k. We further remind readers that the CEO may face performance requirements to receive the non-salary part of the total compensation. We looked at a group of companies with market capitalizations under US$200m, and the median CEO total compensation was US$523k.
As you can see, Vinnie, Vin Milano is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Idera Pharmaceuticals, Inc. is paying too much. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see a visual representation of the CEO compensation at Idera Pharmaceuticals, below.
Is Idera Pharmaceuticals, Inc. Growing?
Over the last three years Idera Pharmaceuticals, Inc. has grown its earnings per share (EPS) by an average of 17% per year (using a line of best fit). Its revenue is up 110% over last year.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Shareholders might be interested in this free visualization of analyst forecasts.
Has Idera Pharmaceuticals, Inc. Been A Good Investment?
With a three year total loss of 85%, Idera Pharmaceuticals, Inc. would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.
We compared the total CEO remuneration paid by Idera Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.
Importantly, though, the company has impressed with its earnings per share growth, over three years. On the other hand returns to investors over the same period have probably disappointed many. While EPS is positive, we'd say shareholders would want better returns before the CEO is paid much more. Shareholders may want to check for free if Idera Pharmaceuticals insiders are buying or selling shares.
Important note: Idera Pharmaceuticals may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.